Isolation, culture, and delivery considerations for the use of mesenchymal stem cells in potential therapies for acute liver failure

Frontiers in Immunology

Immunology

Jun Li¹  Jiaxian Chen¹  Hui Yang¹ 

[1] State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China;

关键词: mesenchymal stem cells (MSCs);    acute liver failure (ALF);    animal models;    culture strategy;    surface markers;    cell therapy;   

DOI  :  10.3389/fimmu.2023.1243220

 received in 2023-06-20, accepted in 2023-08-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

Acute liver failure (ALF) is a high-mortality syndrome for which liver transplantation is considered the only effective treatment option. A shortage of donor organs, high costs and surgical complications associated with immune rejection constrain the therapeutic effects of liver transplantation. Recently, mesenchymal stem cell (MSC) therapy was recognized as an alternative strategy for liver transplantation. Bone marrow mesenchymal stem cells (BMSCs) have been used in clinical trials of several liver diseases due to their ease of acquisition, strong proliferation ability, multipotent differentiation, homing to the lesion site, low immunogenicity and anti-inflammatory and antifibrotic effects. In this review, we comprehensively summarized the harvest and culture expansion strategies for BMSCs, the development of animal models of ALF of different aetiologies, the critical mechanisms of BMSC therapy for ALF and the challenge of clinical application.

【 授权许可】

Unknown   
Copyright © 2023 Yang, Chen and Li